Global CRISPR Gene-Editing Market – Industry Trends and Forecast to 2031

Global CRISPR Gene-Editing Market, By Therapeutic Application (Oncology and Autoimmune or Inflammatory), Application (Genome Engineering, Disease Models, Functional Genomics, and Others), Technology (CRISPR or Cas9, Zinc Finger Nucleases  , and Others),  Services (Design Tools, Plasmid and Vector, Cas9 and g-RNA, Delivery System Products, and Others), Products (GenCrispr or Cas9 kits, GenCrispr Cas9 Antibodies, GenCrispr Cas9 Enzymes, and Others), End-Users (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, and Contract Research Organizations, and Others) – Industry Trends and Forecast to 2031.

CRISPR Gene-Editing Market Analysis and Size

The CRISPR gene-editing market is experiencing rapid growth and is poised to transform the fields of biotechnology, healthcare, and agriculture. The market is primarily driven by the increasing demand for innovative therapies to treat genetic disorders, cancer, and other diseases. CRISPR technology offers a precise and efficient way to edit genes, allowing for the development of targeted therapies that could revolutionize the treatment of various diseases. The application of CRISPR in agriculture is expanding, including its use in developing crops with enhanced yield and resistance to pests and diseases is further driving market growth.

The global CRISPR gene-editing market size was valued at USD 1.41 billion in 2023 and is projected to reach USD 11.36 billion by 2031, with a CAGR of 29.80% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation       

Market Definition

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary gene-editing technology that allows scientists to make precise changes to an organism's DNA. It is based on a natural process used by bacteria to defend against viruses. CRISPR technology has revolutionized genetic research and has the potential to treat genetic disorders, develop new therapies, and improve crop yields.          

CRISPR Gene-Editing Market Dynamics

Drivers

• Growing Demand for Personalized Medicine  

Personalized medicine aims to provide more targeted and effective treatments for various diseases by considering the unique genetic makeup of each patient. CRISPR technology plays a crucial role in this approach by enabling precise modifications to the genome, allowing for the correction of genetic mutations associated with diseases. This ability to tailor treatments to individual genetic profiles has the potential to revolutionize healthcare by improving treatment outcomes and reducing adverse effects, driving the increasing adoption of CRISPR gene editing in medical practice.    

• Rapid Advancements in CRISPR Technology

One major area of advancement is the development of more precise CRISPR systems that can target specific regions of the genome with greater accuracy, reducing the risk of off-target effects. In addition, improvements in delivery methods have made it easier to introduce CRISPR components into cells, enhancing the efficiency of gene editing. These advancements have significantly expanded the potential applications of CRISPR technology, making it a valuable tool in various fields, including the development of novel therapies, the study of gene function, and the creation of genetically modified organisms with beneficial traits. Continuous advancements in CRISPR technology, including improvements in specificity and efficiency, are driving market growth.

Opportunities

• Expansion of Therapeutic Applications  

CRISPR technology has shown promise in treating a wide range of genetic disorders, infectious diseases, and cancer by targeting specific genes associated with these conditions. In the field of genetic disorders, CRISPR has the potential to correct disease-causing mutations, offering a potential cure for genetic diseases that were previously untreatable. In infectious diseases, CRISPR can be used to target and eliminate viral or bacterial DNA, providing a new approach to combating antibiotic-resistant pathogens.  The expansion of CRISPR-based therapeutic applications represents a significant opportunity for market growth.     

• Development of Novel Therapies    

The development of gene therapies that use CRISPR to correct genetic mutations underlying various diseases has shown promise in early clinical trials for conditions such as sickle cell anemia and beta-thalassemia. Another area of innovation is the use of CRISPR in the development of personalized cancer therapies. By targeting specific genetic mutations in a patient's tumor cells, CRISPR can help tailor treatments to individual patients, potentially improving treatment outcomes. CRISPR technology is driving the development of novel therapies that were previously not possible, opening up new opportunities in the pharmaceutical and biotechnology industries.

Restraints/Challenges

• Ethical and Regulatory Challenges        

The ability to make heritable changes to the genome raises complex ethical questions regarding the potential misuse of the technology, the creation of designer babies, and the alteration of future generations' genetic makeup. These concerns have led to calls for strict regulations and guidelines governing the use of CRISPR in human germline editing. In addition, regulatory challenges, such as the need for clear approval processes and oversight mechanisms, further complicate the development and commercialization of CRISPR-based products, creating significant challenges for the market.

• Intellectual Property Disputes

 The CRISPR-Cas9 technology is based on groundbreaking research that has led to the filing of numerous patents by different research groups and institutions. These disputes have resulted in legal battles over patent rights, which could impact the market landscape and slow down the development and commercialization of CRISPR-based products. Ongoing intellectual property disputes over key CRISPR patents represent another challenge for the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In February 2023, Vertex hinted at its launch strategy for the first CRISPR gene editing therapy, pending FDA approval. The therapy, developed in partnership with CRISPR Therapeutics, targets a specific group of patients with severe disease, estimated to be around 32,000 individuals in the U.S. and Europe. These patients are concentrated in specific geographic regions and typically experience frequent vaso-occlusive crises or depend on regular blood transfusions, necessitating multiple hospitalizations annually              
• In March 2021, Setsuro Tech, a Japanese biotech company, secured a patent for CRISPR-Cas9 technology from ERS Genomics, based in Dublin. Setsuro Tech is leveraging this advanced technology to develop animal and cell models, showcasing its commitment to innovative research in the field

CRISPR Gene-Editing Market Scope

The market is segmented on the basis of therapeutic application, application, technology, services, products, and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapeutic Application

• Oncology
• Autoimmune or Inflammatory

Application

• Genome Engineering
• Disease Models
• Functional Genomics
• Others

Technology

• CRISPR or Cas9
• Zinc Finger Nucleases
• Others

Services

• Design Tools
• Plasmid and Vector
• Cas9 and g-RNA
• Delivery System Products
• Others

Products

• GenCrispr or Cas9 kits
• GenCrispr Cas9 Antibodies
• GenCrispr Cas9 Enzymes
• Others

End-Users

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations
• Others

CRISPR Gene-Editing Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, therapeutic application, application, technology, services, products, and end-users as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to substantial investments from biotechnology and pharmaceutical companies. In addition, the region's expanding healthcare infrastructure is expected to enhance market growth during the forecast period further.     

Asia-Pacific is expected to witness significant growth during the forecast period due to the rising per capita income in the region. Moreover, early access to authorized therapies is anticipated to drive market growth in Asia-Pacific in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and CRISPR Gene-Editing Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Applied StemCell (U.S.)
• ACEA BIO (U.S.)
• Synthego (U.S.)
• Thermo Fisher Scientific (U.S.)
• GenScript (China)
• Addgene (U.S.)
• Merck KGaA (Germany)
• Intellia Therapeutics, Inc. (U.S.)
• Cellectis (France)
• Precision Biosciences (U.S.)
• Caribou Biosciences, Inc. (U.S.)
• Transposagen Biopharmaceuticals, Inc. (U.S.)
• OriGene Technologies, Inc. (U.S.)
• Novartis AG (Switzerland)
• New England Biolabs (U.S.)
• Rockland Immunochemicals Inc. (U.S.)
• ToolGen, Inc. (South Korea)
• TAKARA BIO INC. (Japan)
• Agilent Technologies, Inc. (U.S.)
• Abcam plc (U.K.)
• CRISPR Therapeutics AG (Switzerland)